ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - irinotecan hydrochloride - תמיסה לאינפוזיה - irinotecan hydrochloride 20 mg/ml - irinotecan - irinotecan - campto is indicated for the treatment of patients with metastatic colorectal cancer: in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.

ישראל - עברית - Ministry of Health

novapharma ltd - irinotecan (trihydrate) hydrochloride 20 mg/ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - irinotecan hydrochloride trihydrate 20 mg / 1 ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.

ישראל - עברית - Ministry of Health

pharmalogic ltd - irinotecan hydrochloride trihydrate 20 mg / 1 ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - irinotecan hydrochloride trihydrate - תרכיז להכנת תמיסה לאינפוזיה - irinotecan hydrochloride trihydrate 20 mg/ml - irinotecan

ישראל - עברית - Ministry of Health

a.l. medi-market ltd. - irinotecan hydrochloride trihydrate - תרכיז להכנת תמיסה לאינפוזיה - irinotecan hydrochloride trihydrate 20 mg / 1 ml - irinotecan

ישראל - עברית - Ministry of Health

bayer israel ltd - regorafenib - טבליות מצופות פילם - regorafenib 40 mg - regorafenib - regorafenib - stivarga is indicated for the treatment of patients with metastatic colorectal cancer (crc) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf therapy, and if kras wild-type, an anti-egfr therapy.for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumors (gist) who have been previously treated with imatinib mesylate and sunitinib malate

ישראל - עברית - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

ישראל - עברית - Ministry of Health

merck serono ltd - cetuximab - תמיסה לאינפוזיה - cetuximab 5 mg/ml - cetuximab - cetuximab - erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (egfr) - expressing, kras wild-type metastatic colorectal cancer• in combination with irinotecan-based chemotherapy• in first-line in combination with folfox• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanerbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (scchn)• in combination with radiation therapy for locally advanced disease• in combination with platinum-based chemotherapy for recurrent and/or metastatic disease• as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease

ישראל - עברית - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.